"Chemo, Immunotherapy Feasible In Metastatic Bladder Cancer"
Gemcitabine and cisplatin (GC) plus ipilimumab is associated with a 69 percent objective response rate and 61 percent one-year overall survival for patients with metastatic urothelial cancer, according to a study published in European Urology. Matthew Galsky, MD, director of the novel therapeutics program at the Tisch Cancer Institute and professor of urology, medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, conducted a multicenter phase 2 study enrolling 36 chemotherapy-naïve patients with metastatic urothelial cancer. "Because chemotherapy and immunotherapy are the two pillars of treatment for metastatic bladder cancer, we sought to better understand how these treatments might be best given together," Dr. Galsky said. "Already the results of this trial have inspired the creation of two more trials that seek to better the treatment of bladder cancer patients by combining chemotherapy with immunotherapy."
- Matthew Galsky, MD, Director, The Novel Therapeutics Program, Clinical Trials Program, Genitourinary Medical Oncology, The Tisch Cancer Institute at Mount Sinai, Professor, Urology, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
- Andrew Uzilov, PhD, Director of Cancer Genomics, Sema4
- Huan Wang, PhD, Bioinformatics Scientist, Sema4
Additional coverage:
European Pharmaceutical Review
Physician’s Weekly
Renal & Urology News